Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2016
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:developed_by |
gptkb:Teva_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cinqair
|
| gptkbp:ingredients |
gptkb:reslizumab
|
| gptkbp:is_used_for |
gptkb:asthma
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:marketed_as |
gptkb:Cinqair
|
| gptkbp:targets |
eosinophilic asthma
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
gptkb:reslizumab |
| gptkbp:bfsLayer |
6
|